20 results on '"Génestie C"'
Search Results
2. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)
3. 92P Tumour-infiltrating immune cells as a predictive factor in advanced or metastatic leiomyosarcomas: Comparison between uterine and non-uterine tumors
4. 59P Expression of CD47 a potent ‘don’t eat me signal' in ovarian cancer (OC): Correlation with other immune features and evolution under neoadjuvant chemotherapy (NACT), a GINEGEPS study
5. 774P CCNE1 amplification defines a good prognostic subgroup among BRCAwt/HRDneg advanced high-grade ovarian cancer (HGOC)
6. 182MO Immune co-regulator (co-reg) expression in mismatch repair-deficient (MMRd) endometrial cancer (EC) patients (pts): Anti-PD-(L)1-responders (R) versus (vs) non-responders (NR)
7. 584P Mutation analysis of ovarian carcinoma patients presenting optimal response to neoadjuvant chemotherapy
8. 574P Myriad MyChoice plus intermediate performance to discriminate platinum-resistant high-grade ovarian cancer patients
9. 587P Sequential approach to determine the HRD status with BRCA1 promotor methylation status and shallow whole genome sequencing (sWGS)
10. 550P Immunoprofiling of mismatch repair-deficient (MMRd) endometrial cancer (EC) patients (pts): Immune checkpoint inhibitor (ICI)-responders (R) versus non-responders (NR)
11. 801P Response to first-line platinum chemotherapy in microsatellite instability high (MSI-H) metastatic endometrial carcinoma
12. 741P Immune features of high-grade ovarian cancer associated with exceptional disease free survival (DFS): An analysis from VIVROVAIRE, a GINECO/GINEGEPS study
13. 727P Phase Ib INEOV neoadjuvant trial of the anti-PDL1, durvalumab (D) +/- anti-CTLA4 tremelimumab (T) with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): A GINECO study
14. 848P Features and clinical outcomes for younger women with epithelial ovarian cancer (EOC)
15. 135P - Combined tumor-based BRCA/TP53 mutation testing in ovarian cancer
16. EP-1505: Multimodal management of locally advanced neuroendocrine cervical carcinoma
17. 1475PD - A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide and cisplatin (API), followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). Update at 10 years
18. 948P - Genomic instability is associated with increased immune infiltration and PDL1 expression in epithelial ovarian cancer
19. 939PD - An increased ratio of cytotoxic to suppressive T cells after neoadjuvant chemotherapy (NACT) is prognostic in advanced ovarian cancer
20. PO-0962: Adjuvant brachytherapy as a part of a multimodal treatment for high-grade uterine sarcoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.